Monash University and Brigham and Women’s Hospital (BWH) today announce the renewal of their landmark research partnership at a ceremony in Boston, Massachusetts. Australia’s largest university and one of Boston’s largest hospitals are advancing innovation in sleep and circadian medicine through a world-leading research initiative that will include investigating the […]
Other News
The AI Conversation Sleep Medicine Isn’t Having
Here’s an uncomfortable exercise. Tomorrow morning, walk through your sleep lab or practice and ask one question: “Has anyone here ever used ChatGPT, Claude, Gemini, or another AI tool for work?” If the answer is no, chances are someone isn’t being completely honest. Artificial intelligence has become part of the […]
Can a Handheld Device Teach Your Patients to Breathe Their Way to Better Sleep?
Most sleep clinicians know the evidence for slow-paced breathing. Fewer have found a practical way to get patients to actually do it consistently, in the dark, without reaching for their phone. That gap is what moonbird was designed to close. Moonbird is a handheld tactile breath pacer: it expands and […]
ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options
ŌURA maker of the world’s most trusted smart ring, Oura Ring, and LillyDirect, Eli Lilly and Company’s digital health platform designed to connect people living with chronic conditions to the care, support, and prescribed medicines they need, today announced a collaboration enabling savings on the Oura Ring sizing kit. The […]
SLEEP 2026: What Stood Out From Baltimore
The 40th annual SLEEP meeting drew its usual crowd of clinicians, researchers, technologists, and industry representatives to Baltimore — but this year’s meeting felt different in at least one important way. The pharmaceutical presence on the exhibit floor and in sponsored symposia has grown substantially over the past decade, and […]
ProSomnus and MonitAir Collaborate to Enhance Connected Care for OSA
ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“MonitAir”), the premier digital health and tele-monitoring platform for sleep medicine announced a collaboration to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ […]
Jazz Delivers Extensive Data at SLEEP 2026, Real-World Impact of Xywav on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals plc delivered 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic […]
The Syn-Sleep Study: Detection of Cutaneous Phosphorylated Alpha-Synuclein in REM Sleep Behavior Disorder
On Wednesday morning, CND Life Sciences presented exciting new data at SLEEP 2026 from the NIH-sponsored Syn-Sleep Study, indicating that its Syn-One Test detected phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (RBD). SleepWorld had a chance to sit down with CND Chief Medical Officer and […]
New Study Shows Inspire Therapy Helps Reduce Hypoxic Burden
Inspire Medical Systems, Inc. participated in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS) on June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research […]
New Study: Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for Narcolepsy Type 1
New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]













